Lilly Sees Path for Zepbound’s Label Expansion With Phase III Sleep Apnea Win

[cafead]

via Eli Lilly on Friday unveiled detailed findings from the Phase III SURMOUNT-OSA program, showing that its blockbuster weight-loss drug Zepbound (tirzepatide) could significantly improve disease severity in patients with moderate-to-severe obstructive sleep apnea and obesity.

article source